Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002164 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
A Phase 1 study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00002164 is a Phase 1 study that has completed, run by Agouron Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT00002164, a Phase 1 study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the single dose pharmacokinetic profile of Viracept pediatric powder formulation administered to HIV infected or exposed children and infants (0 to 13 years of age). An evaluation of the relative bioavailability of the pediatric powder formulation vs. a standard tablet formulation in older children (7 to 13 years of age) will also be conducted.
Interventions
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002164
The ClinicalTrials.gov registry entry for NCT00002164 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agouron Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir mesylate is the first listed.
NCT00002164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002164 about?
NCT00002164 is a clinical study titled "Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants". To evaluate the single dose pharmacokinetic profile of Viracept pediatric powder formulation administered to HIV infected or exposed children and infants (0 to 13 years of age). An evaluation of the relative bioavailability of the pediatric powder formulation vs. a standard tablet formulation in old...
What is the current status of trial NCT00002164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants.
What interventions are being tested in trial NCT00002164?
The interventions under investigation include: Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002164?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.